The Efficacy and Safety of Resection Plus Neoadjuvant Hepatic Arterial Infusion Chemotherapy Compared With Resection Alone in Patients With Resectable Hepatocellular Carcinoma Beyond Milan Criteria
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 252
- 试验地点
- 7
- 主要终点
- Overall survival
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of resection plus neoadjuvant hepatic arterial infusion chemotherapy (HAIC) compared with resection alone in patients with resectable hepatocellular carcinoma beyond Milan criteria.
详细描述
Resection is the long-term therapeutic option for resectable hepatocellular carcinoma (HCC) patients. While a number of studies demonstrate poor effect and high relapse rate of resection for patients with resectable hepatocellular carcinoma beyond Milan criteria. Our previous prospective study also revealed that neoadjuvant transarterial chemoembolization (TACE) seems to confer a survival benefit for resectable HCC. Recently, the results of our previous prospective study suggested that, compared with TACE, hepatic arterial infusion chemotherapy (HAIC) may improve the survivals for HCC with large HCC.Thus, the investigators carried out this prospective randomized control to demonstrate the superiority of resection plus neoadjuvant HAIC over resection alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL;
- •Tumor burden beyond Milan criteria
- •Diagnosed as resectable with consensus by the panel of liver surgery experts;
- •No past history of resection, radiofrequency ablation, TACE, TAI, chemotherapy or molecule-targeted treatment;
- •No Cirrhosis or cirrhotic status of Child-Pugh class A only;
- •Meet the following laboratory parameters:(a) Platelet count ≥ 75,000/μL; (b)Hemoglobin ≥ 8.5 g/dL;(c) Total bilirubin ≤ 30mmol/L;(d) Serum albumin
- •≥ 32 g/L;(e) ASL and AST ≤ 6 x upper limit of normal;(f) Serum creatinine
- •≤ 1.5 x upper limit of normal;(g) INR > 2.3 or PT/APTT within normal limits; (h) Absolute neutrophil count (ANC) >1,500/mm3;
- •Ability to understand the protocol and to agree to and sign a written informed consent document. Exclusion Criteria;
- •Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
- •Known of serious heart disease which can nor endure the treatment such as cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
- •Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
- •Known history of HIV
- •History of organ allograft
- •Known or suspected allergy to the investigational agents or any agent given in association with this trial.
- •Evidence of bleeding diathesis.
- •Any other hemorrhage/bleeding event > CTCAE Grade 3
- •Serious non-healing wound, ulcer, or bone fracture
- •Known central nervous system tumors including metastatic brain disease
- •Poor compliance that can not comply with the course of treatment and follow up.
排除标准
- 未提供
研究组 & 干预措施
Resection plus HAIC with FOLFOX
Patients receive 4 times of neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX and hepatic resection
干预措施: FOLFOX (Drug)
Resection plus HAIC with FOLFOX
Patients receive 4 times of neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX and hepatic resection
干预措施: Hepatic resection (Procedure)
Resection
Patients receive hepatic resection without neoadjuvant hepatic arterial infusion chemotherapy
干预措施: Hepatic resection (Procedure)
结局指标
主要结局
Overall survival
时间窗: 60 months
Time to death
次要结局
- Disease-free survival(60 months)
- Adverse Events(30 days)
研究者
Ming Shi
Proffessor
Sun Yat-sen University